Literature DB >> 33655926

Fibrodysplasia ossificans progressiva in a young adult with genetic mutation: Case report.

Zhankui Wang1,2, Xiuhua Wang1,2, Baojin Liu3, Yanfeng Hou1,2.   

Abstract

RATIONALE: Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by congenital skeletal deformities and soft tissue masses that progress into heterotopic ossification. Deformities of the great toes are distinctive and heterotrophic ossification usually begins in the first decade of the patient's life. Any invasive procedure could potentially trigger a flare and heterotopic calcification. The diagnosis is difficult and there is no effective treatment for FOP and the approximate life expectancy is 4 decades. PATIENT CONCERNS: A 22-year-old male patient who had suffered from pain and movement limitations for 14 years. At the early stage of disease, the child underwent an operation on both thighs with a diagnosis of myophagism. He had serious stiffness and multiple bony masses with the characteristic bilateral hallux valgus deformity and microdactyly. DIAGNOSES: The patient was diagnosed with FOP by the help of characteristic great toe malformations and widespread heterotopic ossification throughout the body. Deoxyribonucleic acid sequencing demonstrated that the patient had a de novo heterozygous mutation (c.617G>A; p.R206H) in activin A receptor/activin-like kinase 2.
INTERVENTIONS: We administered a co-therapy of glucocorticoids, NSAIDs to relieve pain, and montelukast for 2 months. Bisphosphonate (5 mg, intravenous) was used once. OUTCOMES: At the follow-up 12 months later, the patient still felt low back pain sometimes and need take NSAIDs three times a week. LESSONS: Clinicians and radiologists should realize the characteristic features of FOP and early diagnosis can prevent additional invasive harm to the patient.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33655926      PMCID: PMC7939192          DOI: 10.1097/MD.0000000000024620

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  21 in total

1.  Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva.

Authors:  Richard F Scarlett; David M Rocke; Sharon Kantanie; Jean B Patel; Eileen M Shore; Frederick S Kaplan
Journal:  Clin Orthop Relat Res       Date:  2004-06       Impact factor: 4.176

2.  A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.

Authors:  Celia L Gregson; Peter Hollingworth; Martin Williams; Kirsten A Petrie; Alex N Bullock; Matthew A Brown; Jon H Tobias; James T Triffitt
Journal:  Bone       Date:  2010-10-29       Impact factor: 4.398

Review 3.  Fibrodysplasia ossificans progressiva: Review and research activities in Japan.

Authors:  Nobuhiko Haga; Yasuharu Nakashima; Hiroshi Kitoh; Junji Kamizono; Takenobu Katagiri; Hideto Saijo; Sho Tsukamoto; Yusuke Shinoda; Ryoko Sawada; Yasuo Nakahara
Journal:  Pediatr Int       Date:  2020-01       Impact factor: 1.524

4.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

5.  Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.

Authors:  Michael P Whyte; Deborah Wenkert; Jennifer L Demertzis; Edward F DiCarlo; Erica Westenberg; Steven Mumm
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

6.  Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Michael A Zasloff; Joseph A Kitterman; Eileen M Shore; Charles C Hong; David M Rocke
Journal:  J Bone Joint Surg Am       Date:  2010-03       Impact factor: 5.284

Review 7.  Osteochondral diseases and fibrodysplasia ossificans progressiva.

Authors:  Antonio Morales-Piga; Frederick S Kaplan
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

8.  A Case of Fibrodysplasia Ossificans Progressiva in a 5-year-old Boy with all Musculoskeletal Features and Review of the Literature.

Authors:  Melih Civan; Fuat Bilgili; Ayse Kilic; ZeyraOya Uyguner; Guven Toksoy
Journal:  J Orthop Case Rep       Date:  2018 Sep-Oct

9.  A recurrent mutation c.617G>A in the ACVR1 gene causes fibrodysplasia ossificans progressiva in two Chinese patients.

Authors:  Yue Sun; Weibo Xia; Yan Jiang; Xiaoping Xing; Mei Li; Ou Wang; Huabing Zhang; Yingying Hu; Huaicheng Liu; Xunwu Meng; Xueying Zhou
Journal:  Calcif Tissue Int       Date:  2009-03-20       Impact factor: 4.333

10.  Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements.

Authors:  Renata Bocciardi; Domenico Bordo; Marco Di Duca; Maja Di Rocco; Roberto Ravazzolo
Journal:  Eur J Hum Genet       Date:  2008-10-01       Impact factor: 4.246

View more
  1 in total

1.  Fibrodysplasia ossificans progressiva: A rare disease with spinal deformity and severe hip dysfunction.

Authors:  Dong Sun; Peng Liu; Zhaolin Wang; Jianhu Mu; Jian Cao
Journal:  Front Pediatr       Date:  2022-09-15       Impact factor: 3.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.